Zenas BioPharma, Inc. 1Q 2026: Revenue $16.91M, EPS ($1.46) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
Zenas BioPharma, Inc. reported Q1 2026 revenue of $16.91M, up 69.1% from $10M a year ago, but incurred a net loss of $80.99M compared to $33.57M previously. Diluted EPS was ($1.46), worsening from ($0.8). Key developments include successful Phase 3 trial results for obexelimab, planned regulatory filings, ongoing Phase 2 trials, and pipeline expansion with new licenses. The company expects its cash runway to support operations until 2029, facilitating continued clinical advancements.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments